Genflow Biosciences announced progress in its patent portfolio for its centenarian-derived SIRT6 gene variant, which is central to its longevity research. The US patent application for using this variant to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been published, and prioritized examination was granted for a foundational US patent application. Additionally, the corresponding European patent application is at an advanced stage. These developments support Genflow's strategy to protect its gene therapy innovations aimed at age-related diseases and metabolic liver conditions, with ongoing clinical trials underway.
Jyske Bank continues its 2026 share repurchase program, acquiring shares valued at approximately DKK 1.51 billion as of early August. The program, running from February 2026 to January 2027, allows the bank to buy back shares up to a total value of D...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of the latest transactions in late July 2026, the bank has repurchased 1,642,524 shares at an average price of DKK ...
During week 31 of 2026 (July 27-31), Sampo Oyj bought back a total of 1,729,195 of its A-shares at a weighted average price of €9.59 per share. This share repurchase is part of a buyback program authorized by the company's annual general meeting on A...
Worldline has finalized the sale of its payment activities in India to BillDesk for approximately €60 million in equity value. Alongside the sale, Worldline and BillDesk agreed on a long-term technology and software partnership, allowing BillDesk to ...
Worldline has finalized the sale of its Indian payment activities to BillDesk for an estimated equity value of around €60 million. Alongside the sale, Worldline and BillDesk have agreed on a long-term technology and software partnership, allowing Bil...
